Business / Finance

RSS

ITOCHU CHEMICAL FRONTIER makes strategic investment in SCILEX Pharmaceuticals

SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced that ITOCHU CHEMICAL FRONTIER Corporation (ICF, Tokyo Japan), a member of ITOCHU Corporation, one of the three leading sogo shosha (general trading companies) in Japan, has made a strategic investment in SCILEX.

31 Mar 2015

IDT supports unique bioengineering public outreach program

To help the general public understand how bioengineering is changing the world for the better, Integrated DNA Technologies (IDT) is supporting a unique public outreach program led by expert plant synthetic biologists at Revolution Bioengineering.

From Integrated DNA Technologies 31 Mar 2015

Aeterna Zentaris inks Material Transfer Agreement with MUSC

Aeterna Zentaris Inc. today announced that it has agreed to transfer its discovery library of roughly 100,000 unique compounds to the South Carolina Center for Therapeutic Discovery & Development (the Center) pursuant to a just concluded Material Transfer Agreement.

31 Mar 2015

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2014.

31 Mar 2015

Broad Institute expands collaboration with Bayer to develop new cardiovascular therapies

The Broad Institute of MIT and Harvard have expanded their collaboration with Bayer HealthCare to include cardiovascular genomics and drug discovery. The goal of this new part of the alliance is to leverage insights from human genetics to help create new cardiovascular therapies.

31 Mar 2015

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies.

30 Mar 2015

Thermo Fisher Scientific to resell Prosolia’s PaperSpray® technology as factory option to its mass spectrometers

Labs performing clinical research and forensic toxicology of dried sample spots can now purchase Thermo Scientific mass spectrometry (MS) systems equipped from the factory with PaperSpray technology, designed to virtually eliminate sample preparation for screening and quantitation of drugs in biological fluid samples.

From Thermo Fisher Scientific Inc. 30 Mar 2015

Biosafe acquires ACTS do Brasil's biosafe-related business

After a successful partnership of 10 years with its local distributor ACTS do Brasil Ltda., effective immediately Biosafe has acquired all ACTS' Biosafe-related business, which has been spun off into a separate operating entity, Biosafe Brasil Distribuidora Ltda. Terms have not been disclosed.

30 Mar 2015

European Commission clears Zimmer's proposed acquisition of Biomet

Zimmer Holdings, Inc. announced today that the European Commission has conditionally cleared Zimmer's proposed acquisition of Biomet, Inc. The EC's clearance is conditioned upon Zimmer entering into agreements with a suitable buyer to divest certain assets comprising the remedy package previously submitted to the EC.

30 Mar 2015

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.

30 Mar 2015

HGS acquires majority stake in Colibrium

Hinduja Global Solutions Limited, announced acquisition of majority stake in Colibrium Partners LLC and Colibrium Direct LLC. The acquisition has been made by HGS Colibrium Inc, a US subsidiary of HGS, which would own 89.9% of Colibrium and the balance will be held by the founders. For the year ended 31st December 2014, Colibrium reported revenues of US$ 12.6 mn.

30 Mar 2015

DePuy Synthes inks sales agreement with Radlink to offer real-time image guidance with hip replacement systems

DePuy Synthes Companies has signed an exclusive worldwide sales agreement with Radlink, Inc., an emerging global leader in advanced medical imaging technology, to offer real-time image guidance with its hip replacement systems. The agreement further demonstrates DePuy Synthes Companies’ ongoing commitment to help improve patient outcomes, increase patient satisfaction and reduce costs.

27 Mar 2015

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao.

26 Mar 2015

Philips enters into collaboration with Janssen to develop new handheld blood test to support care of patients with neuropsychiatric disorders

Royal Philips today announced that it has entered into a multi-year development agreement with Janssen Pharmaceutica N.V. (Janssen).

From Philips Healthcare 26 Mar 2015

Nanolek, Green Cross sign strategic deal to commercialize biologics in the Russian market

Green Cross, a South Korean biopharmaceutical company, and Nanolek, a Russian pharmaceutical company, today announced that they have entered into a strategic partnership agreement for the commercialisation of Green Cross' biologics in the Russian market.

26 Mar 2015

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.

26 Mar 2015

AstraZeneca, HSCI collaborate to find new treatments for diabetes

AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

26 Mar 2015

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio.

26 Mar 2015

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.

26 Mar 2015

Lycera achieves milestone in Merck research collaboration

Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.

25 Mar 2015

Business / Finance

ITOCHU CHEMICAL FRONTIER makes strategic investment in SCILEX Pharmaceuticals

IDT supports unique bioengineering public outreach program

Aeterna Zentaris inks Material Transfer Agreement with MUSC

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

Broad Institute expands collaboration with Bayer to develop new cardiovascular therapies

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Thermo Fisher Scientific to resell Prosolia’s PaperSpray® technology as factory option to its mass spectrometers

Biosafe acquires ACTS do Brasil's biosafe-related business

European Commission clears Zimmer's proposed acquisition of Biomet

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

HGS acquires majority stake in Colibrium

DePuy Synthes inks sales agreement with Radlink to offer real-time image guidance with hip replacement systems

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Philips enters into collaboration with Janssen to develop new handheld blood test to support care of patients with neuropsychiatric disorders

Nanolek, Green Cross sign strategic deal to commercialize biologics in the Russian market

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

AstraZeneca, HSCI collaborate to find new treatments for diabetes

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Lycera achieves milestone in Merck research collaboration

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News